The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Premature Ovarian Failure Cure Market Research Report 2025
Synopsis
Premature ovarian failure (POF, also called primary ovarian insufficiency or early menopause) is a common gynecological endocrine disease characterized by the loss of ovarian function in women below 40 years. Most often, it is a non-reversible pathology leading to infertility. Normally, ovaries produce hormones and eggs until the early fifties, when they stop working and most women enter menopause. However, phenomena such as the dysfunction and the depletion of follicles (the cellular aggregates in the ovaries secreting hormones that influence the menstrual cycle) lead to POF, whose prevalence is 1/250 in women under 35 years and 1/100 in women under 40 years; the consequent loss of ovarian reserve (the number of follicles remaining in a woman’s ovaries) increases the risk of infertility, severely affecting women both physically and mentally.
The global Premature Ovarian Failure Cure market was valued at US$ 874.9 million in 2023 and is anticipated to reach US$ 1483.7 million by 2030, witnessing a CAGR of 7.6% during the forecast period 2024-2030.
Pfizer and Bayer are the top two manufacturers of premature ovarian failure cure globally and account for over 30% of global market share in total. Geographically speaking, North America holds about 45% of global market share, followed by Asia-Pacific with over 25% share. In terms of type, hormone replacement therapy (HRT) segment holds an important share of about 50%. In terms of application, 20 to 30 years old holds over 45% of total market share.
This report aims to provide a comprehensive presentation of the global market for Premature Ovarian Failure Cure, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Premature Ovarian Failure Cure.
Report Scope
The Premature Ovarian Failure Cure market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Premature Ovarian Failure Cure market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Premature Ovarian Failure Cure companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Bayer
Novartis
Bioscience Institute
Johns Hopkins Medicine
Mayo Clinic
Baptist Health
Indira IVF
Segment by Type
Hormone Replacement Therapy (HRT)
Calcium and Vitamin D Supplements
In Vitro Fertilization (IVF)
Stem Cell Therapy
Others
Segment by Application
Less than 20 Years Old
20 to 30 Years Old
30 to 45 Years Old
45 Years Old and Older
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Premature Ovarian Failure Cure companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Premature ovarian failure (POF, also called primary ovarian insufficiency or early menopause) is a common gynecological endocrine disease characterized by the loss of ovarian function in women below 40 years. Most often, it is a non-reversible pathology leading to infertility. Normally, ovaries produce hormones and eggs until the early fifties, when they stop working and most women enter menopause. However, phenomena such as the dysfunction and the depletion of follicles (the cellular aggregates in the ovaries secreting hormones that influence the menstrual cycle) lead to POF, whose prevalence is 1/250 in women under 35 years and 1/100 in women under 40 years; the consequent loss of ovarian reserve (the number of follicles remaining in a woman’s ovaries) increases the risk of infertility, severely affecting women both physically and mentally.
The global Premature Ovarian Failure Cure market was valued at US$ 874.9 million in 2023 and is anticipated to reach US$ 1483.7 million by 2030, witnessing a CAGR of 7.6% during the forecast period 2024-2030.
Pfizer and Bayer are the top two manufacturers of premature ovarian failure cure globally and account for over 30% of global market share in total. Geographically speaking, North America holds about 45% of global market share, followed by Asia-Pacific with over 25% share. In terms of type, hormone replacement therapy (HRT) segment holds an important share of about 50%. In terms of application, 20 to 30 years old holds over 45% of total market share.
This report aims to provide a comprehensive presentation of the global market for Premature Ovarian Failure Cure, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Premature Ovarian Failure Cure.
Report Scope
The Premature Ovarian Failure Cure market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Premature Ovarian Failure Cure market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Premature Ovarian Failure Cure companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Bayer
Novartis
Bioscience Institute
Johns Hopkins Medicine
Mayo Clinic
Baptist Health
Indira IVF
Segment by Type
Hormone Replacement Therapy (HRT)
Calcium and Vitamin D Supplements
In Vitro Fertilization (IVF)
Stem Cell Therapy
Others
Segment by Application
Less than 20 Years Old
20 to 30 Years Old
30 to 45 Years Old
45 Years Old and Older
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Premature Ovarian Failure Cure companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Premature Ovarian Failure Cure Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Hormone Replacement Therapy (HRT)
1.2.3 Calcium and Vitamin D Supplements
1.2.4 In Vitro Fertilization (IVF)
1.2.5 Stem Cell Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Premature Ovarian Failure Cure Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Less than 20 Years Old
1.3.3 20 to 30 Years Old
1.3.4 30 to 45 Years Old
1.3.5 45 Years Old and Older
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Premature Ovarian Failure Cure Market Perspective (2019-2030)
2.2 Premature Ovarian Failure Cure Growth Trends by Region
2.2.1 Global Premature Ovarian Failure Cure Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Premature Ovarian Failure Cure Historic Market Size by Region (2019-2024)
2.2.3 Premature Ovarian Failure Cure Forecasted Market Size by Region (2025-2030)
2.3 Premature Ovarian Failure Cure Market Dynamics
2.3.1 Premature Ovarian Failure Cure Industry Trends
2.3.2 Premature Ovarian Failure Cure Market Drivers
2.3.3 Premature Ovarian Failure Cure Market Challenges
2.3.4 Premature Ovarian Failure Cure Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Premature Ovarian Failure Cure Players by Revenue
3.1.1 Global Top Premature Ovarian Failure Cure Players by Revenue (2019-2024)
3.1.2 Global Premature Ovarian Failure Cure Revenue Market Share by Players (2019-2024)
3.2 Global Premature Ovarian Failure Cure Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Premature Ovarian Failure Cure Revenue
3.4 Global Premature Ovarian Failure Cure Market Concentration Ratio
3.4.1 Global Premature Ovarian Failure Cure Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Premature Ovarian Failure Cure Revenue in 2023
3.5 Premature Ovarian Failure Cure Key Players Head office and Area Served
3.6 Key Players Premature Ovarian Failure Cure Product Solution and Service
3.7 Date of Enter into Premature Ovarian Failure Cure Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Premature Ovarian Failure Cure Breakdown Data by Type
4.1 Global Premature Ovarian Failure Cure Historic Market Size by Type (2019-2024)
4.2 Global Premature Ovarian Failure Cure Forecasted Market Size by Type (2025-2030)
5 Premature Ovarian Failure Cure Breakdown Data by Application
5.1 Global Premature Ovarian Failure Cure Historic Market Size by Application (2019-2024)
5.2 Global Premature Ovarian Failure Cure Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Premature Ovarian Failure Cure Market Size (2019-2030)
6.2 North America Premature Ovarian Failure Cure Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Premature Ovarian Failure Cure Market Size by Country (2019-2024)
6.4 North America Premature Ovarian Failure Cure Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Premature Ovarian Failure Cure Market Size (2019-2030)
7.2 Europe Premature Ovarian Failure Cure Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Premature Ovarian Failure Cure Market Size by Country (2019-2024)
7.4 Europe Premature Ovarian Failure Cure Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Premature Ovarian Failure Cure Market Size (2019-2030)
8.2 Asia-Pacific Premature Ovarian Failure Cure Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Premature Ovarian Failure Cure Market Size by Region (2019-2024)
8.4 Asia-Pacific Premature Ovarian Failure Cure Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Premature Ovarian Failure Cure Market Size (2019-2030)
9.2 Latin America Premature Ovarian Failure Cure Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Premature Ovarian Failure Cure Market Size by Country (2019-2024)
9.4 Latin America Premature Ovarian Failure Cure Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Premature Ovarian Failure Cure Market Size (2019-2030)
10.2 Middle East & Africa Premature Ovarian Failure Cure Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Premature Ovarian Failure Cure Market Size by Country (2019-2024)
10.4 Middle East & Africa Premature Ovarian Failure Cure Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Premature Ovarian Failure Cure Introduction
11.1.4 Pfizer Revenue in Premature Ovarian Failure Cure Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Bayer
11.2.1 Bayer Company Detail
11.2.2 Bayer Business Overview
11.2.3 Bayer Premature Ovarian Failure Cure Introduction
11.2.4 Bayer Revenue in Premature Ovarian Failure Cure Business (2019-2024)
11.2.5 Bayer Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Premature Ovarian Failure Cure Introduction
11.3.4 Novartis Revenue in Premature Ovarian Failure Cure Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Bioscience Institute
11.4.1 Bioscience Institute Company Detail
11.4.2 Bioscience Institute Business Overview
11.4.3 Bioscience Institute Premature Ovarian Failure Cure Introduction
11.4.4 Bioscience Institute Revenue in Premature Ovarian Failure Cure Business (2019-2024)
11.4.5 Bioscience Institute Recent Development
11.5 Johns Hopkins Medicine
11.5.1 Johns Hopkins Medicine Company Detail
11.5.2 Johns Hopkins Medicine Business Overview
11.5.3 Johns Hopkins Medicine Premature Ovarian Failure Cure Introduction
11.5.4 Johns Hopkins Medicine Revenue in Premature Ovarian Failure Cure Business (2019-2024)
11.5.5 Johns Hopkins Medicine Recent Development
11.6 Mayo Clinic
11.6.1 Mayo Clinic Company Detail
11.6.2 Mayo Clinic Business Overview
11.6.3 Mayo Clinic Premature Ovarian Failure Cure Introduction
11.6.4 Mayo Clinic Revenue in Premature Ovarian Failure Cure Business (2019-2024)
11.6.5 Mayo Clinic Recent Development
11.7 Baptist Health
11.7.1 Baptist Health Company Detail
11.7.2 Baptist Health Business Overview
11.7.3 Baptist Health Premature Ovarian Failure Cure Introduction
11.7.4 Baptist Health Revenue in Premature Ovarian Failure Cure Business (2019-2024)
11.7.5 Baptist Health Recent Development
11.8 Indira IVF
11.8.1 Indira IVF Company Detail
11.8.2 Indira IVF Business Overview
11.8.3 Indira IVF Premature Ovarian Failure Cure Introduction
11.8.4 Indira IVF Revenue in Premature Ovarian Failure Cure Business (2019-2024)
11.8.5 Indira IVF Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
